

## DAFTAR PUSTAKA

- Arbiser JL, Elsey J. 2018. Targeting the plasticity of psoriasis. *J Invest Dermatol*. 138:734-736.
- Bangert CA, Costner MI. 2007. Methotrexate in dermatology. *Dermatologic Therapy*. 20:216-228.
- Benhadou F, Mintoff D, del Marmol V. 2018. Psoriasis: keratinocytes or immune cells, which is the trigger?. *Dermatology*. 235:91-100.
- Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan. 2006. Quality of life in patients with psoriasis. *Health and Quality of Life Outcomes*. 4:1-7.
- Budini SS, Cholis M, Rofiq A. 2014. Kadar TNF- $\alpha$  lesi kulit dengan derajat keparahan psoriasis vulgaris. *Berkala Ilmu Kesehatan Kulit dan Kelamin*. 26(1):22-28.
- Buj R, Aird KM. 2018. Deoxyribonucleotide triphosphate metabolism in cancer and metabolic disease. *Front Endocrinol*. 9:1-10.
- Cappellini MD, Motta I. 2015. Anemia in clinical practice, definition and classification: Does Hb change with aging?. *Semin Hematol*. 1-24
- Colombo GL, Altomare GF, Peris K, Martini P, Quarta G, Congedo M, Costanzo A, Cesare AD, Lapucci E, Chimenti S. 2008. Moderate and severe plaque psoriasis: cost of illness study in Italy. *Therapeutical and Clinical Risk Management*. 4(2):559-568.
- Dahlan MS. 2010. Menggunakan rumus besar sampel secara benar. In: Dahlan MS, editor, Besar sampel dan cara pengambilan sampel. 3<sup>rd</sup> ed. Jakarta: Penerbit Salemba Medika; pp. 35-80.
- Dogra S, Mahajan R. 2013. Systemic methotrexate therapy for psoriasis: past, present, and future. *Clinical and Experimental Dermatology*. 38:573-588.
- Dupuis EC, Bhole VM, Dutz JP. 2012. Differing patterns of methotrexate use for psoriatic disease among dermatologists and rheumatologists. *Br J Dermatol*. 167(2):448-450.
- Feldman SR, Krueger GG. 2005. Psoriasis assessment tools in clinical trials. *Ann Rheum Dis*. 64:65-68.
- Ferrelli C, Pinna AL, Pilloni L, Tomasini CF, Rongioletti F, 2018 Histopathological aspects of psoriasis and its uncommon variants. *Giornale Italiano Dermatologia e Venereologia*. 152(2):173-184.
- Gisondi P, Giglio MD, Girolomi G. 2017. Treatment approaches to moderate to severe psoriasis. *Int J Mol Sci*. 18:1-8.
- Greb JE, Goldminz AM, Gottlieb AB. 2016. Insights on methotrexate in psoriatic disease. *Clinical Immunology*. 1-16.
- Gudjonsson JE, Elder JT. Psoriasis. 2012. Dalam: Wolff K, Goldsmith LA, Katz SI, Gilchrist BA, Paller AS, Leffel DJ. *Fitzpatrick's Dermatology in General Medicine*. 8<sup>th</sup> ed. New York: McGraw-Hill; pp.197-231.

- Gulliver WP, McDonald D, Gladney N, Alaghebandan R, Rahman P, Adam BK. 2011. Long term prognosis and comorbidities associated with psoriasis in the Newfoundland and Labrador founder population. *J Cutan Med Surg.* 15:37-47.
- Gyulai R, Bagot M, Griffiths CE, Luger T, Naldi L, Paul C, Puig L, Kemeny L. 2014. Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists. *JEADV.* 29:294-231.
- Hendarwan H, Yuniar Y, Despitasi M. 2018. Kefarmasian dan alat kesehatan. Dalam: Supriyanto, Ardyanto TD, Wibowo DB. *Harapan, Kenyataan, dan Solusi JKN dalam Rangkaian Diskusi Panel Indonesia Healthcare Forum.* Lembaga Penerbit Balitbangkes, Jakarta. P:109-137.
- Henseler T, Christophers E. 1985. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. *J Am Acad Dermatol.* 13:450-456.
- Herrmann T, Buhnerkempe M, Wilson ML. 2019. Initiation of methotrexate with or without a test dose: a retrospective toxicity study. *J am Acad Dermatol.* 80:1160-1162.
- Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. 2005. Translating the science of quality of life into practice: what do dermatology life quality index scores mean?. *J Invest Dermatol.* 125:659-664.
- Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. 2016 Preventing and managing toxicities of high-dose methotrexate. *Oncologist.* 21(12):1471-1482.
- Jundt JW, Browne BA, Fiocco GP, Steele AD, Mock D. 1993. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. *J Rheumatol.* 20(11):1845–1849.
- Katugampola RP, Lewis VJ, Finlay AY. 2007. The dermatological life quality index: assessing the efficacy of biological therapies for psoriasis. *British Journal of Dermatology.* 156:945-950.
- Kaul R, Sanjay CJ. 2010. Review on pulse therapy: a novel approach in the treatment of pemphigus vulgaris. *JIAOMR.* 22:211-214.
- Kemenkes RI. 2017. *Keputusan menteri kesehatan republik Indonesia nomor HK.01.07/MENKES/659/2017 tentang formularium nasional.* Departemen Kesehatan RI, Jakarta.
- Kim WB, Jerome D, Yeung J. 2017. Diagnosis and management of psoriasis. *Can Fam Physician.* 63:278-285.
- Li D, Yang Z, Kang P, Xie X. 2016. Subcutaneous administration methotrexate at high doses makes better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate. *Semin Arthritis Rheum.* 45(6):656-662.
- Li J, Li X, Hou R, Liu R, Zhao X, Dong F, Wang C, Yin G, Zhang K. 2015. Psoriatic T cells reduce epidermal turnover time and affect cell proliferation contributed from differential gene expression. *J Dermatol.* 42(9):874-880.

- Li Y, Jiang L, Zhang S, Yin L, Ma L, He D, Shen J. 2012. Methotrexate attenuates the Th17/IL-17 levels in peripheral blood mononuclear cells from healthy individuals and RA patients. *Rheumatol Int.* 32:2415-2422.
- Menting SP, Dekker PM, Limpens J, Hooft L, Spuls PI. 2016. Methotrexate dosing regimen for plaque-type psoriasis: a systematic review of the use of test-dose, start-dose, dosing scheme, dose adjustments, maximum dose and folic acid supplementation. *Acta Derm Venereol.* 96:23-28.
- Mahler V, Diepgen T, Skudlik C, Becker D, Dickel H, Fartasch M, Geier, Haberle M, Hillen U, Krohn S, John SM, Weisshaar, Werfel T, Zagrodnik F. 2014. Psoriasis predisposition and occupational triggering factors in the appraisal of occupational medical expertise. *JDDG.* 4:519-529.
- Manalo IF, Gilbert KE, Wu JJ. 2015. Subcutaneous methotrexate for symptomatic control of severe recalcitrant psoriasis. *Psoriasis Targets and Therapy.* 5:65-70.
- Mylonas A, Conrad C. 2018. Psoriasis: classical vs paradoxical, the yin-yang of TNF and type I interferon. *Front Immunol.* 9:1-10.
- Nast A, Amelunxen L, Augustin M, Boehncke WH, Dressler C, Gaskins M, Harle P, Hoffstadt B, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Rzany B, Schlaeger M, Ott GS, Sebastian M, con Kiedrowski R, Weberschock T. 2018. S3 guideline for the treatment of psoriasis vulgaris, update - short version part 1 - systemic treatment. *JDDG.* 16(5): 645-669.
- Ni C, Chiu MW. 2014. Psoriasis and comorbidities: links and risks. *Clinical, Cosmetic, and Investigational Dermatology.* 7:1-14.
- Operacz MC, Przytocka AS. 2014. The possibilities and principles of methotrexate treatment of psoriasis: the updated knowledge. *Postep Derm Alergol.* 6:392-400.
- Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. 2013. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. *J Invest Dermatol.* 133:377-385.
- Puig L. 2014. Methotrexate: new therapeutic approaches. *Actas Dermosifiliogr.* 105(6):583-589.
- Putra PB, Rahmawati KN, Yulinvia AT, Radiono S, Oktarina DA. 2018, *In press.* Clinical and life quality improvement, and IL-17 serum level in psoriasis patients treated with methotrexate injection: a pilot study in 15 severe psoriasis cases. *Scitepress*
- Rademaker M, Gupta M, Andrews M, Armour K, Baker C, Foley P, Gebaur K, George J, Rubel D, Sullivan J. 2016. The Australasian psoriasis collaboration view on methotrexate for psoriasis in the Australasian setting. *Australasian Journal of Dermatology.* 58(3):166-170.
- Reich K, Domm S, Mrowietz U. 2012. Methotrexate therapy in dermatology. *JDDG.* 5:363-370.

- Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M. 2008. Relationship between clinical response to therapy and health related quality of life outcomes in patients with moderate to severe plaque psoriasis. *Dermatology*. 216:260-270.
- Robert JG, Chalmers MB. 2015. Assessing psoriasis severity and outcomes for clinical trials and routine clinical practice. *Dermatol Clin*. 33:57-71.
- Shen S, O'Brien T, Yap LM, Prince HM, McCormack CJ. 2012. The use of methotrexate in dermatology. 53:1-18.
- Shikiar R, Wilian MK, Okun MM, Thompson CS, Revicki DA. 2006. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients. *Health and Quality of Life Outcomes*. 4:1-12.
- Singh P, Soyer HP, Wu J, Salmhofer W, Gilmore S. 2011. Tele-assessment of psoriasis area and severity index: a study of the accuracy of digital image capture. *Australasian Journal of Dermatology*. 52:259-263.
- Singh RK, Lee KM, Ucmak D, Brodsky M, Atanelov Z, Farahnik B, Abrouk M, Nakamura M, Zhu TH, Liao W. 2016. Erythrodermic psoriasis: pathophysiology and current treatment perspectives. *Psoriasis*. 6:93-104.
- Swierkot J, Slezak R, Karpinski P, Pawlowska J, Noga L, Szechinski J, Wiland P. 2015. Associations between single-nucleotide polymorphisms of RFC-1, GGH, MTHFR, TYMS, and TCII genes and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis. 125(3):152-61.
- Takahashi C, Kaneko Y, Okano Y, Taguchi H, Oshima H, Izumi K, Yamaoka K, Takeuchi T. 2017. Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. *RMD Open*. 3:1-9.
- Tian H, Cronstein BN. 2007. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. *Bull NYU Hosp Jt Dis*. 65:168-173.
- Tonini G, Lamberti A, Guidi I, Cinnoti E, Rubegni P. 2019. Mucocutaneous ulcers as forerunners of methotrexate toxicity. *Dermatol Ther*. 32:1-9.
- Vena GA, Cassano N, Lannone F. 2018. Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis. *Therapeutics and Clinical Risk Management*. 14:105-116.
- Vidal D, Salleras M, Romani J, Ribera M, Gallardo F, Vinas M, Xifra A, Garcia NX, Bordas X, Ferran M, Carrascosa JM. 2016. Adherence of self-administered subcutaneous methotrexate in patients with chronic plaque-type psoriasis. *J Eur Acad Dermatol Venereol*. 30(11):131-132.
- Vide J, Magina S. 2017. Moderate to severe psoriasis treatment challenges through the era of biological drugs. *An Bras Dermatol*. 92(5):668-674.
- Wang W, Shou H, Liu L. 2018. Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review. *Eur J Med Chem*. 158:502-516.
- Warren RB, Mrowietz U, Kiedrowski RV, Niesmann J, Theis DM, Ghoreschi K, Zschocke I, Falk TM, Schlicht NB, Reich K. 2016. An intensified dosing

- schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicenter, randomized, double blind, placebo controlled, phase 3 trial. *Lancet*. 389:528-537.
- Warren RB, Weatherhead SC, Smith CH, Exton LS, Mustapa MF, Kirby B, Yesudian PD. 2016. British association of dermatologist guideline for the safe and effective prescribing of methotrexate for skin disease 2016. *British Journal of Dermatology*. 175:23-44.
- WHO, 2000. *Obesity: preventing and managing the global pandemic*. World Health Organization, Geneva.
- West J, Ogston S, Foerster J. 2016. Safety and efficacy of methotrexate in psoriasis: A meta-analysis of published trials. *PLoS ONE*. 11(5):1-14.
- Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, Shin DB, Attor R, Troxel AB, Gelfand JM. 2013. Psoriasis severity and the prevalence of major co-morbidities: A population based study. *JAMA Dermatol*. 149(10):1173-1179.
- Zargari O, Hejazi S, Shahidi-Dadras M, Younespour S, Robati R, Firooz A, Toosi P, Feldman SR. 2014. Considerable variation among Iranian dermatologists in the dosing and monitoring of methotrexate for treating psoriasis. *Int J Dermatol*. 53(3):385-389.
- Zurita CC, Perez MG, Fernandez CP, Quesada AG, Almazan PV, Alejo JV, Hernandez GC. 2017. Effectiveness and safety of methotrexate in psoriasis: an 8-year experience with 218 patients. *Journal of Dermatological Treatment*. 28(5): 401-405.
- Zweegers J, de Jong EM, Nijsten TE, de Bes J, te Booij M, Borgonjen RJ, van Cranenburgh OD, van Deutekom H, van Everdingen JJ, de Groot M, Van Hees CL, Hulshuizen H, Koek MB, de Korte WJ, de Korte J, Lecluse LL, Pasch MC, Poblete-Gutiérrez PA, Prens EP, Seyger MM, Thio HB, Torcque LA, de Vries AC, van de Kerkhof PC, Spuls PI. 2014. Summary of the Dutch S3-guidelines on the treatment of psoriasis 2011: Dutch Society of Dermatology and Venereology. *Dermatol Online J*. 20(3): 1-113.